The fungal disease drug developer pulled in $60.8m from investors including Novo, which is switching board members at the company.
Pharmaceutical firm Novo’s corporate venturing unit, Novo Ventures, joined unnamed new and existing investors to provide $60.8m in financing for UK-based fungal infection drug developer F2G on Wednesday.
F2G is working on therapeutics for life-threatening fungal diseases and is the creator of a class of antifungal agents known as orotomides which target resistant and rare fungal mould infections.
The capital will go to a phase 2b clinical trial for the company’s lead agent, Olorofim, for fungal infections including invasive aspergillosis,…
